Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors

David M. Ross, Chris Arthur, Kate Burbury, Brian S. Ko, Anthony K. Mills, Jake Shortt, Karam Kostner

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Several BCR-ABL1 tyrosine kinase inhibitors (TKIs) are approved for the first-line treatment of chronic phase chronic myeloid leukaemia (CML). Disease control is achieved in the vast majority of patients and disease-specific survival is excellent. Consequently, there is now emphasis on managing comorbidities and minimising treatment-related toxicity. Second-generation TKIs have cardiovascular risks that are greater than with imatinib treatment, but these risks must be balanced against the superior CML responses encountered with more potent TKIs. Cardiovascular risk should be assessed at baseline using a locally validated model based on the Framingham risk equation. Clinicians involved in the care of CML patients should be aware of the vascular complications of TKIs and manage cardiovascular risk factors early to mitigate treatment-related risks. Reversible risk factors, such as dyslipidaemia, smoking, diabetes and hypertension, should be addressed. We summarise the available data on cardiovascular complications in CML patients treated with TKIs. Using the latest evidence and collective expert opinion, we provide practical advice for clinicians to assess, stratify and manage cardiovascular risk in people with CML receiving TKI therapy.

Original languageEnglish
Pages (from-to)5-13
Number of pages9
JournalInternal Medicine Journal
Volume48
DOIs
Publication statusPublished - 1 Feb 2018

Keywords

  • cardiovascular risk
  • chronic myeloid leukaemia
  • tyrosine kinase inhibitor

Cite this

Ross, David M. ; Arthur, Chris ; Burbury, Kate ; Ko, Brian S. ; Mills, Anthony K. ; Shortt, Jake ; Kostner, Karam. / Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy : assessment and management of cardiovascular risk factors. In: Internal Medicine Journal. 2018 ; Vol. 48. pp. 5-13.
@article{d373290ad8c9425cad8c540475913cfb,
title = "Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors",
abstract = "Several BCR-ABL1 tyrosine kinase inhibitors (TKIs) are approved for the first-line treatment of chronic phase chronic myeloid leukaemia (CML). Disease control is achieved in the vast majority of patients and disease-specific survival is excellent. Consequently, there is now emphasis on managing comorbidities and minimising treatment-related toxicity. Second-generation TKIs have cardiovascular risks that are greater than with imatinib treatment, but these risks must be balanced against the superior CML responses encountered with more potent TKIs. Cardiovascular risk should be assessed at baseline using a locally validated model based on the Framingham risk equation. Clinicians involved in the care of CML patients should be aware of the vascular complications of TKIs and manage cardiovascular risk factors early to mitigate treatment-related risks. Reversible risk factors, such as dyslipidaemia, smoking, diabetes and hypertension, should be addressed. We summarise the available data on cardiovascular complications in CML patients treated with TKIs. Using the latest evidence and collective expert opinion, we provide practical advice for clinicians to assess, stratify and manage cardiovascular risk in people with CML receiving TKI therapy.",
keywords = "cardiovascular risk, chronic myeloid leukaemia, tyrosine kinase inhibitor",
author = "Ross, {David M.} and Chris Arthur and Kate Burbury and Ko, {Brian S.} and Mills, {Anthony K.} and Jake Shortt and Karam Kostner",
year = "2018",
month = "2",
day = "1",
doi = "10.1111/imj.13716",
language = "English",
volume = "48",
pages = "5--13",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell",

}

Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy : assessment and management of cardiovascular risk factors. / Ross, David M.; Arthur, Chris; Burbury, Kate; Ko, Brian S.; Mills, Anthony K.; Shortt, Jake; Kostner, Karam.

In: Internal Medicine Journal, Vol. 48, 01.02.2018, p. 5-13.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy

T2 - assessment and management of cardiovascular risk factors

AU - Ross, David M.

AU - Arthur, Chris

AU - Burbury, Kate

AU - Ko, Brian S.

AU - Mills, Anthony K.

AU - Shortt, Jake

AU - Kostner, Karam

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Several BCR-ABL1 tyrosine kinase inhibitors (TKIs) are approved for the first-line treatment of chronic phase chronic myeloid leukaemia (CML). Disease control is achieved in the vast majority of patients and disease-specific survival is excellent. Consequently, there is now emphasis on managing comorbidities and minimising treatment-related toxicity. Second-generation TKIs have cardiovascular risks that are greater than with imatinib treatment, but these risks must be balanced against the superior CML responses encountered with more potent TKIs. Cardiovascular risk should be assessed at baseline using a locally validated model based on the Framingham risk equation. Clinicians involved in the care of CML patients should be aware of the vascular complications of TKIs and manage cardiovascular risk factors early to mitigate treatment-related risks. Reversible risk factors, such as dyslipidaemia, smoking, diabetes and hypertension, should be addressed. We summarise the available data on cardiovascular complications in CML patients treated with TKIs. Using the latest evidence and collective expert opinion, we provide practical advice for clinicians to assess, stratify and manage cardiovascular risk in people with CML receiving TKI therapy.

AB - Several BCR-ABL1 tyrosine kinase inhibitors (TKIs) are approved for the first-line treatment of chronic phase chronic myeloid leukaemia (CML). Disease control is achieved in the vast majority of patients and disease-specific survival is excellent. Consequently, there is now emphasis on managing comorbidities and minimising treatment-related toxicity. Second-generation TKIs have cardiovascular risks that are greater than with imatinib treatment, but these risks must be balanced against the superior CML responses encountered with more potent TKIs. Cardiovascular risk should be assessed at baseline using a locally validated model based on the Framingham risk equation. Clinicians involved in the care of CML patients should be aware of the vascular complications of TKIs and manage cardiovascular risk factors early to mitigate treatment-related risks. Reversible risk factors, such as dyslipidaemia, smoking, diabetes and hypertension, should be addressed. We summarise the available data on cardiovascular complications in CML patients treated with TKIs. Using the latest evidence and collective expert opinion, we provide practical advice for clinicians to assess, stratify and manage cardiovascular risk in people with CML receiving TKI therapy.

KW - cardiovascular risk

KW - chronic myeloid leukaemia

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85041291100&partnerID=8YFLogxK

U2 - 10.1111/imj.13716

DO - 10.1111/imj.13716

M3 - Review Article

VL - 48

SP - 5

EP - 13

JO - Internal Medicine Journal

JF - Internal Medicine Journal

SN - 1444-0903

ER -